Wells Fargo & Company Forecasts Strong Price Appreciation for Globus Medical (NYSE:GMED) Stock

Key Points

• Wells Fargo raised its price target on Globus Medical from $99 to $100 and maintained an Overweight rating, implying 33.35% upside from the cited share price.
• Analyst views are mixed: BMO downgraded the stock to Market Perform and cut its target to $78, while the overall analyst consensus remains Moderate Buy with a $97 target.
• Globus Medical beat quarterly EPS estimates ($1.23 versus $1.20) but missed revenue expectations, with revenue down 0.7% year over year; its shares were reported down 7.9%.

Globus Medical (NYSE:GMED - Get Free Report) had its price objective upped by investment analysts at Wells Fargo & Company from $99.00 to $100.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the medical device company's stock. Wells Fargo & Company's target price suggests a potential upside of 33.35% from the company's current price.

Other equities research analysts also recently issued research reports about the company. BMO Capital Markets downgraded Globus Medical from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $94.00 to $78.00 in a report on Friday. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Globus Medical in a report on Friday, October 9th. Royal Bank Of Canada dropped their target price on Globus Medical from $115.00 to $85.00 and set an "outperform" rating for the company in a research report on Thursday, October 1st. Needham & Company LLC cut their price target on Globus Medical from $117.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday. Finally, BTIG Research reissued a "neutral" rating on shares of Globus Medical in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical has a consensus rating of "Moderate Buy" and a consensus price target of $97.00.

Globus Medical Trading Down 7.9%

Shares of Globus Medical stock opened at $74.99 on Friday. The firm has a market capitalization of $10.07 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.40 and a beta of 0.98. The firm's 50 day moving average is $77.44 and its 200 day moving average is $83.29. Globus Medical has a 1 year low of $72.54 and a 1 year high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, topping analysts' consensus estimates of $1.20 by $0.03. The firm had revenue of $763.72 million for the quarter, compared to analysts' expectations of $792.39 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company's revenue was down .7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts anticipate that Globus Medical will post 4.99 earnings per share for the current year.

Insider Activity

In other news, Director Ann Rhoads sold 5,000 shares of the firm's stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares of the company's stock, valued at approximately $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the transaction, the director owned 15,000 shares in the company, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 60,000 shares of company stock valued at $4,838,400. Insiders own 18.38% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GMED. Sanctuary Advisors LLC boosted its position in shares of Globus Medical by 2.3% during the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company's stock worth $570,000 after purchasing an additional 151 shares in the last quarter. Summitry LLC increased its position in Globus Medical by 2.6% in the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company's stock valued at $707,000 after buying an additional 211 shares in the last quarter. Central Pacific Bank Trust Division increased its holdings in shares of Globus Medical by 7.8% during the third quarter. Central Pacific Bank Trust Division now owns 3,057 shares of the medical device company's stock valued at $229,000 after acquiring an additional 220 shares in the last quarter. Arizona State Retirement System increased its stake in Globus Medical by 0.8% during the 2nd quarter. Arizona State Retirement System now owns 31,077 shares of the medical device company's stock valued at $2,455,000 after purchasing an additional 252 shares in the last quarter. Finally, Angeles Wealth Management LLC raised its holdings in shares of Globus Medical by 5.0% in the 2nd quarter. Angeles Wealth Management LLC now owns 5,894 shares of the medical device company's stock worth $466,000 after acquiring an additional 280 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and above $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, potentially supporting shareholder returns. Third-quarter results and repurchase program
• Positive Sentiment: Needham lowered its price target from $117 to $100 but maintained a Buy rating. The revised target remains above the cited share price of $81.13. Needham analyst recommendations
• Positive Sentiment: The reported acquisition of Synaptive Medical may broaden Globus’s cranial-neurosurgery technology and strengthen its position in that market. Synaptive Medical acquisition
• Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her holdings by 12.38%. One director’s sale does not by itself establish a change in the company’s outlook. Director share sale
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million consensus and fell 0.7% year over year. Full-year revenue guidance of $3.1 billion is below the $3.2 billion analyst estimate, while EPS guidance of $4.95–$5.05 is broadly in line with expectations. Quarterly results and guidance
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target from $94 to $78, citing a more cautious view of the shares. BMO analyst recommendations

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.